Share on StockTwits

Covidien plc (NYSE:COV) will post its Q214 quarterly earnings results on Friday, April 25th. Analysts expect Covidien plc to post earnings of $0.95 per share and revenue of $2.61 billion for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Covidien plc (NYSE:COV) last posted its quarterly earnings results on Friday, January 24th. The company reported $1.00 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.94 by $0.06. The company had revenue of $2.64 billion for the quarter, compared to the consensus estimate of $2.61 billion. During the same quarter in the prior year, the company posted $0.97 earnings per share. The company’s quarterly revenue was down 13.6% on a year-over-year basis. On average, analysts expect Covidien plc to post $4.02 EPS for the current fiscal year and $4.51 EPS for the next fiscal year.

Covidien plc (NYSE:COV) opened at 70.55 on Thursday. Covidien plc has a 52 week low of $53.0496 and a 52 week high of $73.77. The stock’s 50-day moving average is $70.9 and its 200-day moving average is $67.95. The company has a market cap of $31.800 billion and a P/E ratio of 20.51.

The company also recently announced a quarterly dividend, which is scheduled for Monday, May 5th. Investors of record on Monday, April 7th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date of this dividend is Thursday, April 3rd.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Covidien plc in a research note on Tuesday, April 1st. They now have a $77.00 price target on the stock. On the ratings front, analysts at JPMorgan Chase & Co. raised their price target on shares of Covidien plc from $74.00 to $79.00 in a research note on Thursday, March 27th. Finally, analysts at BTIG Research initiated coverage on shares of Covidien plc in a research note on Tuesday, March 11th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $76.60.

Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.